Drug Class Detail

Drug Class TrkA Receptor Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Danusertib PHA-739358 ABL1 Inhibitor 4 AURK Inhibitor (Pan) 11 BCR-ABL Inhibitor 23 FGFR1 Inhibitor 21 RET Inhibitor 36 TrkA Receptor Inhibitor 7 Danusertib (PHA-739358) is a pan-Aurora kinase with additional activity against ABL, FGFR1, RET, TRKA, and BCR-ABL, including the T315I mutant (PMID: 20072840, PMID: 18089710).
GW441756 TrkA Receptor Inhibitor 7 GW441756 is a selective inhibitor of TrkA and blocks cellular processes caused by TrkA overexpression (PMID: 23319303).
HS-345 TrkA Receptor Inhibitor 7 HS-345 inhibits TRKA, potentially resulting in decreased growth and increased apoptosis of TRKA expressing tumor cells (PMID: 23587795).
SIM-89 MET Inhibitor 50 TrkA Receptor Inhibitor 7 SIM-89 is an inhibitor of c-MET, TRKA, and AMPK, which may result in antitumor activity including inhibition of cell proliferation and suppression of cell migration (PMID: 28332364).
Milciclib PHA-848125AC CDK1 Inhibitor 12 CDK2 Inhibitor 16 CDK4 Inhibitor 12 CDK5 Inhibitor 6 CDK7 Inhibitor 9 TrkA Receptor Inhibitor 7 Milciclib (PHA-848125AC) is a TRKA inhibitor with additional activity against CDK1, CDK2, CDK4, CDK5, and CDK7, potentially resulting in decreased tumor cell growth (PMID: 22160853).
Foretinib GSK1363089G|XL880|EXEL-2880 MET Inhibitor 50 ROS1 Inhibitor 14 TrkA Receptor Inhibitor 7 VEGFR2 Inhibitor 34 Foretinib (GSK1363089) is a multi-kinase inhibitor with activity against several receptor tyrosine kinases, including MET, KDR (VEGFR2), as well as ROS1 and NTRK fusions, which may result in decreased tumor angiogenesis and growth (PMID: 19808973, PMID: 26372962, PMID: 29463555).
BMS-754807 ALK Inhibitor 19 Aurka Inhibitors 23 Aurkb Inhibitors 17 IGF-1R Inhibitor 17 MET Inhibitor 50 TrkA Receptor Inhibitor 7 BMS-754807 is a multi-kinase inhibitor with activity against IGF-1R, insulin receptor, MET, ALK, TRKA, TRKB, AURKA, and AURKB, potentially resulting in decreased tumor cell proliferation (PMID: 25748921).
Molecular Profile Protein Effect Treatment Approaches